Abstract Comparative effectiveness research (CER) has become increasing central to clinical research in medicine. CER seeks to conduct clinical trials that compare different commonly used interventions in real-world settings (pragmatic clinical trials) and use a multitude of sources of evidence (including registries and cohort studies) to inform clinical decision making. CER also ensures that stakeholders (patients, families, care providers, insurers) have a voice in the research process by integrating formal stakeholder engagement as part of the research. This innovative approach to clinical research has distinct benefits and pitfalls. This review first defines what CER is and then describes some of its benefits and then pitfalls. The focus is on the role of CER in pediatrics.
Introduction
Clinical researchers are increasingly considering comparative approaches to clinical management and studies of therapeutic effectiveness outside of tightly controlled clinical trial settings. These initiatives have been labeled comparative effectiveness research (CER). In many aspects, researchers have conducted CER without having a clear name for it [1] . CER now refers to specific types of clinical research that prioritize the ability to replicate or maintain real-life clinical practice as a key element of the research design, which is fundamentally different from most traditional clinical research studies [2] . The Institute of Medicine (IOM) has deemed pediatric respiratory disease a key priority area for CER [3] . In this commentary, we first define CER and then provide examples of its implementation in pediatric research. We then describe many of the pros and cons of CER while highlighting the value of this approach to current and future pediatric research studies.
Definition
A number of definitions for CER have been proposed (Table 1) [4, 5] . These definitions share common components: (1) research in ''real-world'' settings with comparisons of therapeutics or treatment approaches that are relevant to clinical decision making; (2) valuing diverse sources of evidence, including observational data; and (3) prioritizing approaches that lead to broad applicability and dissemination of results. CER extends our understanding of evidence-based medicine by shifting greater focus toward key stakeholders-patients, providers, and payers. Continuous engagement with stakeholders is used to refine the research priorities and ensure the research being conducted will serve their needs. Engagement of stakeholders encompasses identification of research topics, and establishing priorities, methodologies, and data syntheses [6] [7] [8] [9] . In pediatric research, stakeholders include both patients and caregivers as well as providers, the pharmaceutical industry, insurers, government agencies, and-oftensupportive foundations [10] . One common approach in CER is to formulate research questions using the PICO framework: a Patient/Problem, Intervention, Comparators, and Outcome [11] .
CER supports using a variety of evidence, including administrative data analysis, systematic reviews, cohort studies, and case-control studies (Table 1) [4] . While these clinical research study designs are not new, CER affords them greater weight than in the traditional hierarchy of evidence-based medicine [12] .
One of the more critical components of study design in CER is the emphasis on pragmatic or practical clinical trials compared with conventional efficacy trials. In pragmatic clinical trials, we assess effectiveness rather than efficacy [2, 13, 14] . Most clinical trials are efficacy trials-they assess whether the therapy or treatment approach works in a tightly controlled setting. Pragmatic clinical trials of effectiveness assess whether the therapy or treatment approach works in the broader population with few interventions other than usual clinical care to promote adherence to a protocol [15, 16] . CER research studies strive to provide information that can be generalized to a broad population affected by the disease or condition of interest.
CER is also characterized by a relatively low intensity of follow-up. In the extreme, investigators conducting a comparative effectiveness study do not interact with the participants outside the confines of usual practice, obtaining data on study outcomes from the medical record alone [13] . CER studies also emphasize active comparator studies without the use of placebo arms. In addition, the rigorous follow-up that is characteristic of an efficacy trial can both limit real-world applicability and potentially influence the observed effect size. Traditional efficacy studies typically limit study enrollment to patients with the disease of interest and without several excluded co-morbidities to optimize statistical power and the assessment of benefit versus risk of participation. In contrast, because an imperative of CER is to be readily generalizable, CER studies have minimal inclusion and exclusion criteria, allowing enrollment of a more broadly representative cohort. Often the inclusion criteria for CER studies mirror common clinical criteria to identify target patients for studies. As an example, in a CER of pediatric asthma, physician-diagnosis of asthma may be used for inclusion rather than measures of lung function and bronchodilator effect.
One of the better examples of the differences between efficacy and effectiveness clinical trials can be observed in the study of patients with mild persistent asthma. Efficacy trials strongly support the use of inhaled corticosteroids as first-line agents in patients with mild persistent asthma [17] . Interestingly, when a pragmatic effectiveness trial was conducted comparing leukotriene-receptor antagonists against inhaled steroids, the authors noted that leukotrienereceptor antagonists were as effective as inhaled corticosteroids for long-term symptom control [18] . These findings were likely due in part to poor adherence with inhaled steroids for the treatment of mild persistent asthma. On a population level, a once-a-day pill such as the leukotrienereceptor antagonists may be as or even more effective than a twice-daily inhaler with spacer intervention because of improved adherence with simple drug regimens [19] .
Benefits of Comparative Effectiveness Research (CER)
One of the true innovations in CER is the inclusion of stakeholder groups throughout the research process. The stakeholder groups have been variably defined but are generally quite broad, including consumers, clinicians, researchers, policymakers, industry representatives, private and public healthcare purchasers, and healthcare leaders [10] . Such engagement can enhance participation in research. By integrating stakeholders into the research priorities, one helps ensure that prioritization emphasizes ''real-world'' research questions that are those most important to the communities impacted by the research.
Another great benefit of CER is the increased likelihood that results of pragmatic trials will reflect and inform reallife clinical care decisions. Prior research in patients with cystic fibrosis (CF) has demonstrated that patients who participate in classic efficacy clinical trials do not closely reflect the broader patient population [20] . The patients who participated in clinical trials had worsened clinical status but less lung disease progression over time [20] . [21, 22] . In this trial, researchers responded to an express desire from the CF community (practitioners, family members, and funding agencies) to design a randomized clinical trial to assess different approaches to eradicate Pseudomonas aeruginosa from the airways of children with CF who had recently acquired the organism. A placebo arm of the trial was rejected by the stakeholder community, whereas four comparative treatment options were included in the study design. Inhaled antibiotics were given either on a set schedule or only when respiratory cultures were positive for P. aeruginosa [22] . Both interventions were deemed acceptable by the CF community. The inclusion criteria were quite broad; only subjects in whom the treatment medications were deemed to be potentially harmful were excluded. The study identified that fewer antibiotics could be used to achieve the same result of P. aeruginosa eradication [22] . Another great advance in CER is the increased flexibility to evaluate a broader range of evidence to establish effectiveness. Evidence can come in the form of secondary data analyses of administrative datasets or of patient registries. Populations studied with both administrative data and disease registries represent a broad spectrum of patients who are managed primarily in real-world conditions. These analyses allow one to study treatment effects that require longer-term observation than is typically feasible in clinical trials (like survival or annualized change in health outcomes over several years). Organizations for rare diseases, such as CF, have developed large-scale patient registries that include data related to demographics, clinical status, and medication use, and provide a key resource for investigating CER questions. The Cystic Fibrosis Foundation has maintained a longstanding patient registry (the CF Foundation Patient Registry [CFFPR]) to track clinical outcomes and clinical care; the data for this registry have gone through formal validation for key variables [23] and are entered soon after clinical encounters to document how care is provided in the current era. This registry has been used to assess the long-term treatment effects of therapies in a broadly representative population of patients with CF and has been able to demonstrate better survival associated with use of specific therapies [24] . Such outcomes would not be feasible in traditional clinical trials. Registries have also been instrumental in evaluating outcomes in CF between countries. One recent study of patient registry data demonstrated that children with CF in the USA have better lung function than those in the UK [25] . Differences in care and the early adoption of therapeutics for children in the USA may account for these differences. In a more recent analysis, patients with CF living in Canada were demonstrated to have a 10-year survival advantage compared with those in the USA. This may be partly attributable to differences in how the therapeutic option of lung transplantation is utilized in the USA compared with Canada [26] .
These examples merely use data captured in each country's respective disease registries. However, there are alternative approaches that exploit administrative data sources maintained by providers and payers of healthcare to identify patients with target conditions. The national effort to develop electronic medical records provides further opportunities to develop methodologies to identify patients [27] . The content of these data systems is expanding beyond diagnostic coding to include medications, laboratory values, cost, provider-level characteristics, and free text. Such data sources can now be used to deploy machine learning to assess the impact of different therapeutic and treatment approaches [28] .
Pitfalls in CER
Rarely do decisions in clinical research come without potential pitfalls, and CER has its own set. One of the most challenging areas is that of the pragmatic clinical trial. If efficacy has not yet been established for a specific intervention through traditional clinical trials, using a pragmatic trial design risks weakening the ability to demonstrate that the therapy works as intended. In this scenario, a failed pragmatic trial may establish that the therapy was ineffective in a heterogeneous population but would not determine whether it has efficacy in a target population. This approach could prematurely or erroneously halt the development of a drug or therapeutic approach. A great example of this phenomenon occurred in asthma therapy; many of the novel biologics for asthma that failed when evaluated in larger heterogeneous populations of patients with asthma (i.e., mepolizumab [29] ) have now been approved by the US FDA for specific sub-phenotypes of asthma. Thus, developing a drug using a personalized approach to therapeutics is in conflict with CER.
Another potential pitfall of CER is that research priorities must emanate from stakeholders. While this approach can prioritize research that the community wants, it may limit the ability of researchers to tackle controversial, challenging, or highly novel clinical research topics. Intense stakeholder involvement may add additional barriers to conducting ground-breaking research that is not understood to address one of the community's greatest needs. Many scientific discoveries have emanated from underappreciated theories or study proposals that the community would reject. A great example of such a research development was that of the discovery of Helicobacter pylori as the causative agent of the majority of peptic ulcer disease [30] . The greater community of academics rejected the H. pylori hypothesis, and one could easily envision stakeholder perspectives that could limit scientific investigation [31] in other fields.
CER is based on the premise that comparing efficacious therapies (active comparator trials) is an integral component of the research. This approach can fail to consider changes in the target patient population over time that may develop with increasing or long-term exposure to treatment. Many active comparator studies require a non-inferiority design rather than a superiority design, which is susceptible to a concern termed ''bio-creep'' [32, 33] . A scenario may develop when additional therapeutics or therapeutic approaches are slightly less effective than the prior treatments but are deemed non-inferior. As additional treatment options are considered, they may become less and less effective but remain non-inferior in active comparator trials. If such options were to be compared with placebo, it could be no better than placebo due to biocreep. Thus, a research strategy that emphasizes active comparator studies using non-inferiority designs (as seen in CER) can be problematic. Superiority trials can overcome this important limitation of serial non-inferiority studies.
Clinical trials typically rely heavily on clinical care outcomes (e.g., survival, health events, physiologic markers, etc.) that work well for clinicians but often fail to specifically address issues that patients and their families may find central to their needs, such as symptoms and treatment burden [34] . CER focuses on patient-centered outcomes. One concern that could be raised about CER is its strong emphasis on patient-centered outcomes. A study may result in improved patient-centered outcomes without improvement in or even worsening of key classically derived clinical endpoints. One could take the extreme position and state that the use of cocaine, for example, improves patient-centered symptoms and patient-reported quality of life; such a therapy could theoretically be deemed an effective therapy to achieve these therapeutic aims, but is this drug a good treatment?
The last major challenge with CER as currently defined is the complete absence of economic analyses integrated into the assessment of therapeutic benefit. Cost-effectiveness analysis (CEA) is an integral component in the development of clinical guidelines in other countries, including Australia, England, and Canada [35] . This exclusion of cost from CER does limit the use of these data in setting health policy and thus also limits the implications of the research. However, the prospect of using this information to make decisions is controversial [1, 36, 37] . A compromise is emerging wherein measuring resource use is desired as long as the combination of costs and health outcomes (e.g., CEA) is not explicitly used to make decisions [37] . Evolution of healthcare in the US marketplace may have longer-term influences on cost evaluations if healthcare costs continue to escalate.
With CER as a growing research modality for populationbased assessments, one must consider the potential conflict with personalized medicine, wherein the goal is to provide tailored treatments to individuals [38, 39] . CER provides data on ''average population effectiveness'' of a particular treatment relative to another, but as variation can exist for any treatment at an individual level, the potential benefits of personalizing a treatment are ignored. Although secondary and subgroup analyses can mitigate some of this potential variation, the ability to adjust for individual-level confounders is limited by the availability and granularity of the datasets used [40] . Conversely, given the current era of limited resources and budgets, CER data can be used to inform personalized medicine such that any investments will yield therapies with significantly improved health outcomes, and in this way act in a complementary manner [40] .
Conclusions
CER appears to be here to stay. This avenue of clinical research has certain real strengths over the more traditional approaches to clinical epidemiology and clinical research. The structure of CER pushes researchers to engage the community and stakeholders early in the development of a research proposal. The transition from efficacy to effectiveness research can give the clinical community a clear vision of how therapies and treatment approaches work in the real world. These data will help support clinicians in their goals to appropriately inform their patients about the likely treatment outcomes that go beyond the results seen in tightly controlled double-blind randomized controlled trials that are the centerpiece of efficacy-based clinical research. Both CER effectiveness trials and classical efficacy trials can and should exist together. Each research approach addresses different research questions and needs to be included in the clinical trial compendium. Ultimately, the choice of study will depend on the questions to be addressed.
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